AQR Arbitrage’s Bio-Rad Laboratories Class A BIO Stock Holding History

AQR Arbitrage’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,235	Closed	-$706K	–	1028
2020 Q4	$706K	Buy	+1,235	New	+$703K	0.02%	544

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AQR Arbitrage's BIO Position: Q1 2021 in Review

AQR Arbitrage sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2021, closing a stake of 1,235 shares — an estimated $706K sold.

AQR Arbitrage first reported a position in BIO in Q4 2020 and held it in 1 quarter. The position peaked at $706K in Q4 2020. 491 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

AQR Arbitrage reported no remaining Bio-Rad Laboratories Class A position as of Q1 2021 after selling out during the quarter.
AQR Arbitrage sold 1,235 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $706K.
AQR Arbitrage first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 1 quarter.
AQR Arbitrage's Bio-Rad Laboratories Class A position peaked at $706K in Q4 2020.
491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on AQR Arbitrage's 13F filing for Q1 2021, filed 17 May 2021.